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The endothelium may play a role as a target and mediator of hypertension. Due to its anatomical position, it is very
exposed to mechanical forces; as a source of vasoactive material it may participate in increasing peripheral vascular
resistance and in promoting local ischaemia in the heart and brain. Morphological and functional changes in the
endothelium occur in experimental and human hypertension. However, the severity of the defect and the mechanisms
involved among vascular beds and models of hypertension are heterogeneous. Endothelium-dependent relaxations are
unpaired in theaorta, carotid artery and in cerebral and mesenteric arterioles in hypertension. In the coronary circulation
the defect is less pronounced. The mechanisms involve a reduced formation of nitric oxide, an enhanced production of
prostaglandin H2 .and an impaired responsiveness of vascular smooth muscle to nitric oxide. The role of endothelin in
hypertension is controversial; circulating levels appear unaltered except in the presence of renal failure or athero-
sclerosis. The local vascular production of endothelin, however, may still be increased. The potentiating effects of
threshold concentrations of endothelin on the vasoconstrictor response to noradrenalin are enhanced in hypertension.
Thus, subtle and distinct endothelial function defects occur in hypertension, but not all vascular beds are similarly
affected and different mechanisms contribute. Endothelial dysfunction may contribute to increased peripheral resistance,
tissue ischaemia and cardiovascular complications.
i
Introduction
Hypertension is characterized by altered haemodynamic
balance, in particular increased peripheral vascular
resistance, as well as increased incidence of cardiovas-
cular complications, such as myocardial infarction and
stroke. The vasculature contributes both as a regulator
of peripheral vascular resistance and as a target of high
blood pressure. The latter alterations induced by hyper-
tensive disease in certain vascular beds is a crucial event
in the development of myocardial infarction and stroke.
The primary structure of the blood vessel wall, which is
most exposed to high blood pressure and hence develops
early morphological and functional alterations, is the
endothelium. The discovery that endothelial cells also
secrete potent vasoactive substances1'"31 which appear to
play an important role in the local regulation of vascular
tone such as nitric oxide'4", prostacyclin'61, endothelin"1
and cyclooxygenase-derived contracting factors'7'
further supports the concept that the endothelial organ
may play an important role in hypertension both as a
mediator and target of the disease.
Eadotbelinm-derived vasoactive mediators
L-ARGININE/NITRIC OXIDE (NO) PATHWAY
In isolated blood vessels, the relaxation evoked by
acetylcholine is abolished by removal of the endothelium
and mediated by nitric oxide (NO) formed from L-argin-
ine (Fig. I<'AO.81J J J ^
 c n Zy r n C ( nitric oxide synthase, is
calcium- and calmodulin-dependent. The release of NO
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can be triggered by shear stress (flow), the calcium iono-
phore A23187, and a number of autocoids, including
bradykinin, histamine, noradrenaline, substance P, vaso-
pressin (in certain arteries), thrombin, and platelet-
derived products (adenosine di- and triphosphate (ADP
and ATP) and serotonin'1"9'). NO has a dual action and
not only evokes relaxation of vascular smooth muscle,
but also inhibits platelet adhesion and aggregation'101.
Both effects require the activity of soluble guanylate
cyclase, which leads to an increase in the intracellular
levels of cyclic 3',5'-guanosine monophosphate (cGMP)
(Fig. I'"1). The L-arginine pathway can be blocked by
various N^-substituted derivatives of L-arginine, such as
L-N°-monomethyl arginine, L-N°-nitroarginine methyl
ester, or L-N-iminoethyl ornithine, which compete with
the precursor of NO'5*1.
PROSTACYCLIN (PGI2)
Endothelial cells are a rich source of PGI2 which
relaxes coronary arteries, increases coronary flow, and
inhibits platelet aggregation'*1. The mechanism of action
of PGI2 involves an increase in cyclic 3',5'-adenosine
monophosphate (cAMP). The production of PGI2 is
stimulated by shear stress, hypoxia, and autacoids,
which release EDRF. However, PGI2 contributes very
little to endothelium-dependent relaxations'2-81.
ENDOTHELJUM-DERIVED HYPERPOLARIZING
FACTOR (EDHF)
In addition to NO, the endothelium releases a hyper-
polarizing factor, at least in certain blood vessels. In
canine coronary arteries, acetylcholine causes an endo-
thelium-dependent hyperpolarization of smooth muscle
cells that is mediated by a diffusible substance'121.
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Figure 1 The endothelial L-arginine nitric oxide (NO) pathway: NO is
formed from L-arginine via the activity of NO synthase, a calcium- and calm-
odulin-dependent enzyme which can be inhibited by analogues of L-arginine
such as L-L-N°-monomethyl arginine ( L - N M M A ) . sGC = soluble guanylate
cyclase, cGMP = cyclycGMP. Reproduced with permission'2'.
Similarly, in porcine coronary arteries, L - N M M A blocks
the response to serotonin but not that to bradykinin'13'.
Debate continues, however, whether at least under cer-
tain conditions, NO or nitrovasodilators can hyperpolar-
ize smooth muscle cells'14'. The endothelium-dependent
hyperpolarization may contibute to the relaxation and/or
reduce the sensitivity of vascular smooth cells of
vasoconstrictor substances.
ENDOTHELIN
Endothelial cells also produce the potent vasoconstric-
tor peptide, endothelin (Fig. 2'3'). The 21-amino-acid
peptide is produced and released by endothelial cells (on
the basis of de novo protein synthesis rather than release
of stored peptide) upon stimulation with thrombin,
transforming growth factor-beta, norepinephrine, phor-
bol ester, and the calcium ionophore A23187 (Fig. 2
"-
3
'
31). Three isoforms exist: endothelin-1, endothelin 2,
and endothelin 3. Endothelial cells appear to produce
primarily endothelin-1. In vascular smooth muscle,
endothelin-1 binds to specific receptors, activates phos-
pholipase, increases intracellular calcium and causes
long-lasting contractions for renin'16'. The peptide has a
greater vasoconstrictor potency than the other cardio-
vascular hormones. In vivo, the circulating levels of the
peptide are extremely low. Threshold concentrations,
however, potentiate contractions evoked by norepine-
phrine and serotonin (Fig. 31'71). In most, but not in all
preparations, NO or nitrovasodilators are able to inhibit
contractions induced by endothelin-11'8191. ln addition,
EDRF or nitrovasodilators inhibit the release of endo-
thelin from intact porcine aorta'15'.
CYCLOOXYGENASE-DEPENDENT CONTRACTING
FACTORS
In certain blood vessels, endothelium-dependent
increases in tension can be obtained with arachidonic
acid, acetylcholine, serotonin and other agonists
(see'1'16'). Most of these responses can be prevented by
cyclooxygenase inhibitors, such as indomethacin or
meclofenamate, suggesting that they are mediated by a
cyclooxygenase-dependent contracting factor (Fig. 2).
Depending on the blood vessels and agonists studied,
the responses also can be prevented by thromboxane
synthetase inhibitors, thromboxane receptor antagonists
or scavengers of oxygen-derived free radicals. These
pharmacological data support the notion that the
cyclooxygenase pathway can produce mediators causing
endothelium-dependent contractions such as thrombo-
xane A2, prostaglandin H2 or superoxide anions'16'.
Although a distinct endothelium-derived contracting
factor released during hypoxia has been proposed, more
recent evidence strongly suggests that endothelium-
dependent contractions to hypoxia are due to removal
of nitric oxide (the production of which is oxygen-depen-
dent) rather than due to the release of contractile
material1201.
Heterogeneity of endothelial dysfunction in hypertension
In isolated arteries obtained from hypertensive
animals with different forms of hypertension, alterations
of endothelial function have been documented by
numerous groups'1'. Similarly, in human hypertension
endothelial dysfunction occurs'21'22'. However, in
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Figure 2 Endothelium-dependent contractions: The endothelium is a source of numerous contracting
factors such as endothelin-1 (ET), thromboxane A2 (TXAi), prostaglandin H2 (PGH2) and possibly also
of angiotensin II (All). The cyclooxygenase pathway is also a source of superoxide anions (O2) which is
able to break down nitric oxide (NO). O = receptors; AA = arachidonic acid; ACE = angiotensin converting
enzyme; Ach = acetylcholine; ATG = angiotensinogen; ADP = adenosine diphosphate; AVP = arginine
vasopressin; Bk = bradylunin; 5HT = serotonin (5-hydroxytryptamine); NE = norepinephrine; PGF-beta =
transforming growth factor beta; Thr = thrombin. Reproduced with permission from the American Heart
Association"".
experimental hypertension, it appears that endothelial
dysfunction is particularly prominent in certain, but not
in all, vascular beds and in addition may be related to
different mechanisms in different vascular beds as well
as in different models of hypertension.
ANATOMICAL HETEROGENEITY
Most studies have been performed in large conduit
arteries, such as the aorta, where reduced endothelium-
dependent relaxations have been described in all rat
models of hypertension. Similarly, in the carotid as well
as the cerebral microcirculation, impaired endothelium-
dependent relaxations or vasodilatation respectively
have been documented in the spontaneously hyperten-
sive rat (Fig. 4123>24)). Similarly, endothelium-dependent
relaxations are impaired in the mesenteric resistance
circulation'231. In contrast, although endothelium-depen-
dent contractions occur in the spontaneously hyperten-
sive rat in the renal circulation, the responses differ very
little from those obtained in normotensive Wistar Kyoto
rats, at least up to an age of 30 weeks123'. In isolated
epicardial coronary arteries of the spontaneously hyper-
tensive rat, endothelium-dependent relaxations do not
differ from those obtained in Wistar Kyoto rats up to
an age of 60 weeks (Fig. 41261). Hence, although altered
endothelium-dependent responses occur in experimental
hypertension of the rat, certain vascular beds, in particu-
lar large coronary and renal arteries, appear to be pro-
tected from the defect, while in other arteries marked
endothelium dysfunction can be noted.
HETEROGENEITY OF SPECIES
Endothelial function has been investigated in experi-
mental hypertension of the rat, rabbit and mouse as well
as in human essential hypertension1'1. In all rat models
of hypertension, impaired endothelium-dependent relax-
ations have been observed, while in the rabbit (which
does develop less pronounced hypertension) very little
Figure 3 Potentiating effects of low and threshold concentrations
of endothelin-1 (ET) in the human internal mammary artery. In
the presence of minute amounts of ET, the response to nore-
pinephrine is enhanced, an effect which is prevented by the dihydro-
piridine calcium antagonist PY (darodipine). Reproduced with
permission from the American Heart Association117'.
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Figure 4 Heterogeneity of endothelial dysfunction in experimental
hypertension. In the thoracic aorta of the spontaneously hyperten-
sive rat (A), endothelium-dependent relaxations to acetylcholine
are markedly reduced as compared to normotensive Wistar-Kycto
rats ( • ) (right panel), while in the coronary artery of the same
animals, the responses are well maintained (left panel). Data repro-
duced from17-231.
alteration has been noted'27' and in psychosocial hyper-
tension in the mouse an enhanced response to endo-
thelium-dependent agonists has even been reported'28'.
In the human forearm circulation of patients with essen-
tial hypertension, two independent research groups have
reported impaired endothelium-dependent vasodilation
to acetylcholine with a preserved or only slightly altered
responsiveness to sodium nitroprusside (Fig. 5l2ia2]).
HETEROGENEITY OF MECHANISMS
An alteration in endothelium-dependent regulation of
vascular tone can involve the endothelial vasodilator as
well as vasoconstrictor systems. In the case of endo-
thelium-dependent relaxations, a reduced response could
involve a specific defect in all or certain receptor-opera-
ted pathways, an impaired production of nitric oxide
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Figure 5 Impaired endothelium-dependent vasodilation in human
essential hypertension. Infusion of acetylcholine in the brachial
artery causes marked decreases in forearm vascular resistance, an
effect which is impaired in hypertensives (B; n - 8 ) as compared
to normotensives ( • ; n = 8). * P=< 005. Reproduced with per-
mission from the American Heart Association121'.
from L-arginine, a reduced smooth muscle responsive-
ness to the endogenous nitrovasodilator and/or a con-
comitant formation of a contracting factor interfering
with the effects of NO.
All of these disturbances have been observed under
certain conditions, but are not uniformly found in all
models of hypertension or all vascular beds studies.
Although an increased medial thickness commonly
occurs in hypertensive arteries, both in conduit vessels
as well as in the resistance circulation, a reduced respon-
siveness to NO donors such as sodium nitroprusside or
SIN-1 is particularly prominent in the aorta and the
carotid artery of the hypertensive rat'23'29', while in mes-
enteric resistance arteries and in large renal arteries the
response to the nitrovasodilators is well maintained'30'.
Even in the presence of an impaired responsiveness to
NO, this alteration does not fully explain the reduced
endothelium-dependent relaxations, as the response to
acetylcholine commonly is much more impaired than
that to nitrovasodilators'30'. Hence, different endothelial
mechanisms must be altered under these conditions.
In the spontaneously hypertensive rat, endothelium-
dependent relaxations are impaired to certain but not all
agonists, although all of them activate specific receptors
linked to the formation of relaxing factors'1'. Indeed, in
the aorta of these animals, the response of acetylcholine
is markedly reduced, while that to thrombin is fully
maintained and that to histamine may actually be
enhanced'17'. This suggests that defects may be quite
specific and must not necessarily involve all pathways
activating endothelial cells.
In mesenteric resistance arteries of the spontaneously
hypertensive and 2-kidney-l clip renovascular hyperten-
sion, the relaxations to acetylcholine are impaired
although that to endothelium-independent vasodilators
such as SIN-1 are normal, suggesting a reduced forma-
tion ofendothelium-derivedNO'2330'31'. In perfused mes-
enteric resistance arteries, intraluminal activation of the
endothelium by acetylcholine is particularly impaired in
hypertension, while extraluminal application of
acetylcholine evokes normal responses'23'. This suggests
that the intraluminal surface of the endothelium, which
is most exposed to high blood pressure, selectively exhib-
its the defect.
In the aorta of the spontaneously hypertensive rat, but
not in that of the Dahl salt-induced hypertensive rat,
acetylcholine causes endothelium-dependent contrac-
tions mediated by prostaglandin H2 (Fig. 6'716'). In this
preparation, antagonists of the thromboxane receptor or
inhibitors of cyclooxygenase (which prevent the forma-
tion of the vasoconstrictor prostanoids) can normalize
the imparied endothelium-dependent relaxations to
acetylcholine. Hence, in this particular preparation an
increased formation of an endothelium-derived contract-
ing factor derived from the cyclooxygenase pathway (i.e.
prostaglandin H2) is responsible for the impaired relaxa-
tions in response to acetylcholine, serotonin and aggre-
gating platelets"61.
The contribution of endothelin in this context remains
uncertain'"1. As judged from the circulating levels of the
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Figure 6 Endothelium-dependent contractors to acetykholine in the aorta of the spontaneously hypertensive
rat. Acetylcholine elicits endothelium-dependent contractions at higher concentrations which are prevented
by the phospholipase A2 quinacrine or the cyclooxygenase inhibitors indomethacin or meclofenomate.
* / ' < 0 0 5 . D=control; • =quinacrine, 10~3M; A = quinacrine, 10~*M; O = indomethacin, 10"5M; • =
meclofenamate, 10~5M. Reproduced with permission from the American Heart Association'71.
peptide in rat and human hypertension it appears that
the production of endothelin is not grossly increased (for
review see1'6') except in the presence of renal failure or
atherosclerosis132'. However, circulating levels of endo-
thelin may not necessarily reflect the local vascular pro-
duction of the peptide, particularly since endothelin is
preferentially released into the abluminal direction. In
addition, the production of the peptide may be increased
in certain but not all vascular beds. An interesting effect
of endothelin in this context is the fact that the peptide,
even at threshold concentrations, can potentiate the
response to other vasoconstrictor hormones, suggesting
that it may act as a regulator of vascular contractility
(see Fig. 3). In ageing and hypertensive rats this indirect
potentiating effect of threshold concentrations of endo-
thelin are augmented133'34'. Angiotensin II expresses
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Figure 7 Stimulation of endothelin (ET) messenger RNA by
angiotensin H in endothelial cells in culture obtained from the por-
cine aorta (A), the rat aorta (B) or from freshly obtained endothel-
ial cells of the mesenteric micTocirculation (C). The increase in
message in the latter cells is quantified in panel D. Reproduced
with permission from the American Heart Association'34'.
endothelin messenger RNA even in the microcirculation
(Fig. 7134') and stimulation with All of perfused mesen-
teric resistance arteries is associated with an endotheli-
um-dependent potentiation of the response to
norepinephrine (Fig. 8|34'). As this response is prevented
by phosphoramidone, an inhibitor of the endothelin con-
verting enzyme, as well as endothelin antibody, this
strongly suggests that angiotensin II is able to stimulate
local vascular endothelin production which then in turn
augments contractile responses to noradrenaline. If this
were to occur in vivo, such response may participate in
the pressure effects of very low concentrations of angio-
tensin II.
6-5 6
Norepinephrine (-logM)
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Figure8 Potentiating effects of angiotensin II (All 10 M) in per-
fused mesenteric resistance arteries with endothelium obtained
from the spontaneously hypertensive rat. Perfusion of the vessels
with All for 5 h increases the response to norepinephrine
(*/><005;**/><001). This endothelium-dependent potentiation
of the response to norepinephrine induced by All is prevented by
either the endothelin converting enzyme inhibitor, phosphorami-
done, or an endothelin antibody. D=control; • = A H ; E3 =
All + phosphoraminadone; B3 = All + endothelin antibody (n = 5).
Reproduced with permission from the American Heart
Association'34'.
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ENDOTHELIAL DYSFUNCTION AND BLOOD PRESSURE
In the Dahl rat, the impairment of endothelium-
dependent relaxations to acetylcholine correlates with
the degree of blood pressure elevation'291. Antihyperten-
sive therapy on the other hand, normalizes the response
in Dahl salt-hypertensive rats'291. Similarly, in the spon-
taneously hypertensive rat, endothelium-dependent
relaxations to acetylcholine are impaired in the mesentric
resistance circulation of adult (>16 weeks of age) but
not of young spontaneously hypertensive rats (6 weeks
of age'25'). As antihypertensive therapy with calcium
antagonists or drugs interfering with the renin angioten-
sin system both prevent this defect, it is likely that the
impaired endothelium-dependent relaxations are a con-
sequence, rather than a cause, of high blood pressure'251.
The authors thank Bernadette Weber-Libsig and Amanda N. de
Sola Pinto for technical assistance. Original research supported in
this article was made possible by grants from the Swiss National
Research Foundation (SCORE Grant 3231-025150, Project Grant
32-25468.88), The Helmut Horton Foundation, the Stanley
Thomas Johnson Foundation and the Sandoz Foundation on Age
Research.
References
[1] Luscher TF, Vanhoutte PM. The Endothelium: Modulator
of Cardiovascular Function. Boca Raton, FL, CRC Press,
1990: 1-215.
[2] Furchgott RF, Zawadzki JV. The obligatory role of endo-
thelial cells in the relaxation of arterial smooth muscle by
acetylcholine. Nature 1980; 299: 373-6.
[3] Yanagisawa M, Kurihara H, Kimura S el al. A novel potent
vasoconstrictor peptide produced by vascular endothelial
cells. Nature 1988; 332: 411-15.
[4] Palmer RMJ, Ferrrige AG, Moncada S. Nitric oxide release
accounts for the biological activity of endothelium-derived
relaxaing factor. Nature 1987; 327: 524-6.
[5] Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial
cells synthesize NO from L-arginine. Nature 1988a; 333:
664-6.
[6] Moncada S, Vane JR. Pharmacology and endogenous roles
of prostaglandin endoperoxides, thromboxane Ai and prosta-
cydin. Pharmacol Rev 1979; 30: 293-31.
[7] Luscher TF, Vanhoutte PM. Endothelium-dependent con-
tractions to acetylcholine in the aorta of the spontaneously
hypertensive rat. Hypertension 1986; 8: 344-8.
[8] Yang Z, von Segesser L, Bauer E, Stulz P, Turina M, Luscher
TF. Different activation of the endothelial L-arginine and
cyclooxygenase pathway in the human internal mammary
artery and saphenous vein. Circ Res 1991; 68: 52-60.
[9] Yang Z, Stulz P, von Segesser L, Bauer E, Turina M, Luscher
TF. Different interactions of platelets with arterial and venous
coronary bypass vessels. Lancet 1991; 337: 939-43.
[10] Radomsky MW, Palmer RMJ, Moncada S. The anti-aggre-
gating properties of vascular endothelium: interactions
between prostacyclin and nitric oxide. Br J Pharmacol 1987;
92:639-46.
[II] Rapoport RM, Murad F. Agonist-induced endothelium-
dependent relaxation in rat thoracic aorta may be mediated
through cGMP. Circ Res 1983; 52: 352-7.
[12] Feletou M, Vanhoutte PM. Endothelium-dependent hyper-
polarization of canine coronary smooth muscle. Br J
Pharmacol 1988; 93: 515-24.
[13] Richard V, Tanner FC, Tschudi M, Luscher TF. Differential
activation of the endothelial L-arginine pathway by bradyki-
nin, serotonin and clonidine in porcine coronary arteries. Am
J Physiol 1990; 259: H1433-H1439.
[14] Tare M, Parkington HC, Coleman HA, Neild TO, Dusting
GJ. Hyperpolarisation and relaxation of arterial smooth
muscle caused by NO derived from the endothelium. Nature
1990; 346: 69-71.
[15] Boulanger C, Luscher TF. Release of endothelin from the
porcine aorta: inhibition by endothelium-derived nitric oxide.
J C1in Invest 1990; 85: 587-90.
[16] Luscher TF, Boulanger Ch, Dohi Y, Yang Z. Endothelium-
derived contracting factors. Hypertension 1992; 19: 117-30.
[17] Yang Z, Richard V, von Segesser L et al. Threshold concen-
trations of endothelin 1 portentiate contractions to norepi-
nephrine and serotonin in human arteries: a new mechanism
of vasospasm? Circulation 1990; 82: 188-95.
[18] Luscher TF, Yang, Z, Tschudi M et al. Interaction between
endothelin-1 and endothelium-derived relaxing factor in
human arteries and veins. Circ Res 1990; 66: 1088-94.
[19] Kiowski W, Luscher TF, Linder L, Buhler TF. Endothelin-1
induced vasoconstriction in man: reversal by calcium channel
blockade but not by nitrovasodilators or endothelium-derived
relaxing factor. Circulation 1991; 83: 469.
[20] Graser T, Vanhoutte PM. Contractoin of canine coronary
arteries to severe hypoxia: Role of endothelium, contraction
level, and cyclic GMP. Am J Physiol (in press).
[21] Linder L, Kiowski W, Buhler Fr, Luscher TF. Indirect evi-
dence for release of endothelium-derived relaxing factor in
human forearm circulation in vivo: blunted response in essen-
tial hypertension. Circulation 190; 81: 1762-7.
[22] Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal
endothelium-dependent vascular relaxation in patients with
essential hypertension. N EngI J Med 1990; 323: 22-7.
[23] Luscher TF, Diederich D, Weber E, Vanhoutte PM, Buhler
FR. Endothelium-dependent responses in carotid and renal
arteries of normotensive and hypertensive rats. Hypertension
1988; 11:573-8.
[24] Mayhan WG, Faraci FM, Heistad DD. Responses of cerebral
arterioles to adenosine 5'-diphosphate, serotonin, and the
thromboxane analogue U-46619 during chronic hypertension.
Hypertension 1988; 12: 556-61.
[25] Dohi, Y, Thiel MA, Buhler FR, Luscher TF. Activation of
endothelial L-arginine pathway in resistance arteries: Effect
of Age and Hypertension. Hypertension 1990; 15: 170-9.
[26] Tschudi MR, Criscione L, LQscher TF. Effect of ageing and
hypertension on endothelial function of rat coronary arteries.
J Hypertension 1991; 9 (Suppl. 6): 164-5.
[27] Wright CE, Angus JA. Effects of hypertension and hyper-
cholesteremia on vasodilatation in the rabbit. Hypertension
1986:8:361-71.
[28] Webb RC, Vander AJ, Henry JP. Increased vasodilator
responses to acetylcholine in psychosocial hypertensive mice.
Hypertension 1987; 9: 268-76.
[29] Luscher TF, Vanhoutte PM, Raij L. Antihypertensive treat-
ment normalizes decreased endothelium-dependent relaxa-
tions in rats with salt-induced hypertension. Hypertension
1987; 9 (Suppl III): IIII93-IIII97.
[30] Diederich D, Yang Z, Buhler FR, Luscher TF. Impaired
endothelium-dependent relaxations in hypertensive resistance
arteries involve the cyclooxygenase pathway. Am J Physiol
1990; 258: H445-H451.
[31] Dohi Y, Criscione L, Luscher TF. Renovascular hypertension
impairs formation of endothelium-derived relaxing factors
and sensitivity to endothelin-1 in resistance arteries. Br J
Pharmacol 1991; 104: 349-54.
[32] Lerman A, Edwards BS, Hallett JW, Heublein DM, Sondberg
SM, Burnett JC Jr. Circulating and tissue endothelin immuno-
reactivity in advanced atherosclerosis. N EngI J Med 1991;
325:997-1001.
[33] Dohi Y, Luscher TF. Aging differentially affects direct and
indirect actions of endothelin-1 in perfused mesenteric arteries
of the rat. Br J Pharmacol 1990; 100: 889-93.
[34] Dohi Y, Hahn AWA, Boulanger Ch, Buscher TF. Endothelin
stimulated by angiotensin II augments contractility of SHR
resistance arteries. Hypertension 1992; 19: 131-7.
